Back to top
more

Insulet (PODD)

(Real Time Quote from BATS)

$182.23 USD

182.23
382,003

+5.04 (2.84%)

Updated Jun 3, 2024 02:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Insulet (PODD) Product Volume Up, COVID-Led Softness Persists

Insulet's (PODD) drug delivery revenues surge led by increased production volumes, driven by higher-than-expected demand from its partner.

Insulet (PODD) Q4 Earnings Surpass Estimates, Margins Up

Insulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets.

Insulet (PODD) Tops Q4 Earnings and Revenue Estimates

Insulet (PODD) delivered earnings and revenue surprises of 40% and 2.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BellRing Brands (BRBR) Beats Q1 Earnings and Revenue Estimates

BellRing Brands (BRBR) delivered earnings and revenue surprises of 8.70% and 1.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold on to Insulet (PODD) Stock for Now

Investors are optimistic about Insulet's (PODD) better-than-expected revenues and solid revenue growth across the Omnipod product line.

Insulet (PODD) Q3 Earnings Miss Estimates, Revenues Top

Insulet (PODD) reports better-than-expected revenues for third-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.

Insulet (PODD) Misses Q3 Earnings Estimates

Insulet (PODD) delivered earnings and revenue surprises of -9.09% and 1.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?

Continued strength in Aurora Cannabis' (ACB) domestic-adult-recreational segment is expected to have driven Q1 sales.

Is a Surprise Coming for Insulet (PODD) This Earnings Season?

Insulet (PODD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Clover Health (CLOV) to Report Q3 Earnings: What's in Store?

Clover Health's (CLOV) third-quarter results are likely to benefit from Direct Contracting and strategic partnerships.

CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?

CVS Health's (CVS) consumer-centric digital approach to administering vaccines across the nation is expected to have strongly contributed to its Q3 performance.

Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?

Strong surgeon registrations of the Signature One surgical planning system for shoulder procedures are likely to have driven Zimmer Biomet's (ZBH) growth in Q3.

Insulet (PODD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Insulet (PODD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charles River (CRL) to Report Q3 Earnings: What's in the Cards?

Robust demand for research models and the Vigene Biosciences buyout are likely to have contributed to growth for Charles River (CRL).

STERIS (STE) to Report Q2 Earnings: What's in the Cards?

Strong gains from the recent Cantel Medical buyout as well as the addition of a new Dental arm are expected to have contributed STERIS' (STE) Q2 performance.

Urmimala Biswas headshot

4 Medical Products Stocks Poised to Beat This Earnings Season

Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.

BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?

Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q4 sales.

AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?

AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?

DENTSPLY SIRONA (XRAY) third-quarter results are likely to reflect strong segmental performance.

IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?

Strong organic recurring revenue growth in CAG diagnostics business and the recent ezyVet buyout are likely to have contributed to growth for IDEXX (IDXX).

What's in Store for Henry Schein (HSIC) in Q3 Earnings?

Strengthening demand in the global dental and medical markets along with the recent investments are likely to have contributed to Henry Schein's (HSIC) Q3 performance.

Conformis (CFMS) to Post Q3 Earnings: What's in the Offing?

Conformis' (CFMS) third-quarter results are likely to reflect strength in core products.

PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?

PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at the Diagnostics segment.

Catalent (CTLT) to Report Q1 Earnings: What's in Store?

Catalent's (CTLT) Biologics segment is likely to have maintained its momentum, thereby aiding Q1 results.

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the third quarter despite the ongoing pandemic-led business challenges.